肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

临床营养作为胰腺癌患者治疗途径的一部分：专家共识 2021

2021-08-02 Clin Transl Oncol . 2021 Aug 7. doi: 10.1007/s12094-021-02674-x

胰腺癌

目的：营养不良是胰腺癌 (PC) 患者的常见问题，会对他们的生活质量 (QoL) 和临床结果产生负面影响。该共识的主要目标是解决医学营养疗法 (MNT) 在 PC 患者综合治疗管理中的作用。

中文标题：

临床营养作为胰腺癌患者治疗途径的一部分：专家共识 2021

发布机构：

发布日期：

2021-08-02

简要介绍：

目的：营养不良是胰腺癌 (PC) 患者的常见问题，会对他们的生活质量 (QoL) 和临床结果产生负面影响。该共识的主要目标是解决医学营养疗法 (MNT) 在 PC 患者综合治疗管理中的作用。

方法：西班牙内科肿瘤学领域的多学科专家组；放射肿瘤学；内分泌学和营养学；和 General Surgery 同意评估 MNT 作为 PC 患者最佳治疗管理的一部分的作用。

结果：专家组制定了不同的建议，重点是营养筛查和营养筛查工具、根据 PC 状态的 MNT 策略以及姑息治疗中的 MNT。

结论：将营养治疗整合为 PC 患者多模式护理过程的关键部分的需求尚未得到满足。卫生当局、医疗保健专业人员、癌症患者及其家人应了解营养状况和 MNT 与 PC 患者临床结果和 QoL 的相关性。

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e2c521c002152592, title=临床营养作为胰腺癌患者治疗途径的一部分：专家共识 2021, enTitle=, guiderFrom=Clin Transl Oncol . 2021 Aug 7. doi: 10.1007/s12094-021-02674-x, authorId=0, author=, summary=目的：营养不良是胰腺癌 (PC) 患者的常见问题，会对他们的生活质量 (QoL) 和临床结果产生负面影响。该共识的主要目标是解决医学营养疗法 (MNT) 在 PC 患者综合治疗管理中的作用。, cover=, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Aug 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>目的：营养不良是胰腺癌 (PC) 患者的常见问题，会对他们的生活质量 (QoL) 和临床结果产生负面影响。该共识的主要目标是解决医学营养疗法 (MNT) 在 PC 患者综合治疗管理中的作用。</p> <p>方法：西班牙内科肿瘤学领域的多学科专家组；放射肿瘤学；内分泌学和营养学；和 General Surgery 同意评估 MNT 作为 PC 患者最佳治疗管理的一部分的作用。</p> <p>结果：专家组制定了不同的建议，重点是营养筛查和营养筛查工具、根据 PC 状态的 MNT 策略以及姑息治疗中的 MNT。</p> <p>结论：将营养治疗整合为 PC 患者多模式护理过程的关键部分的需求尚未得到满足。卫生当局、医疗保健专业人员、癌症患者及其家人应了解营养状况和 MNT 与 PC 患者临床结果和 QoL 的相关性。</p>, tagList=[TagDto(tagId=718, tagName=胰腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=34, categoryName=全科与营养, tenant=100), CategoryDto(categoryId=66, categoryName=营养科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11353, appHits=163, showAppHits=0, pcHits=1045, showPcHits=10800, likes=2, shares=14, comments=9, approvalStatus=1, publishedTime=Thu Aug 12 21:14:29 CST 2021, publishedTimeString=2021-08-02, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Thu Aug 12 21:14:23 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Fri Jan 05 13:27:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1085784, encodeId=5e191085e8436, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Thu Dec 30 11:56:52 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084249, encodeId=289410842490d, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6414873, createdName=ms8000000343428426, createdTime=Sat Dec 25 21:38:15 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083752, encodeId=d7411083e5266, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211025/4aac53d3123446c5af3cebf4df126e53/db970580eb704431af00101c67ba359c.jpg, createdBy=c6221962164, createdName=1e13ac83m50(暂无匿称), createdTime=Fri Dec 24 06:41:31 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069082, encodeId=4bfd106908210, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=289a5704354, createdName=ms1000001851068630, createdTime=Wed Nov 10 21:05:06 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062519, encodeId=f6231062519cd, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:53:45 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-12-30 ms2000002042000994

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1085784, encodeId=5e191085e8436, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Thu Dec 30 11:56:52 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084249, encodeId=289410842490d, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6414873, createdName=ms8000000343428426, createdTime=Sat Dec 25 21:38:15 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083752, encodeId=d7411083e5266, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211025/4aac53d3123446c5af3cebf4df126e53/db970580eb704431af00101c67ba359c.jpg, createdBy=c6221962164, createdName=1e13ac83m50(暂无匿称), createdTime=Fri Dec 24 06:41:31 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069082, encodeId=4bfd106908210, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=289a5704354, createdName=ms1000001851068630, createdTime=Wed Nov 10 21:05:06 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062519, encodeId=f6231062519cd, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:53:45 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-12-25 ms8000000343428426

    👍

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1085784, encodeId=5e191085e8436, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Thu Dec 30 11:56:52 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084249, encodeId=289410842490d, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6414873, createdName=ms8000000343428426, createdTime=Sat Dec 25 21:38:15 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083752, encodeId=d7411083e5266, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211025/4aac53d3123446c5af3cebf4df126e53/db970580eb704431af00101c67ba359c.jpg, createdBy=c6221962164, createdName=1e13ac83m50(暂无匿称), createdTime=Fri Dec 24 06:41:31 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069082, encodeId=4bfd106908210, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=289a5704354, createdName=ms1000001851068630, createdTime=Wed Nov 10 21:05:06 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062519, encodeId=f6231062519cd, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:53:45 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-12-24 1e13ac83m50(暂无匿称)

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1085784, encodeId=5e191085e8436, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Thu Dec 30 11:56:52 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084249, encodeId=289410842490d, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6414873, createdName=ms8000000343428426, createdTime=Sat Dec 25 21:38:15 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083752, encodeId=d7411083e5266, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211025/4aac53d3123446c5af3cebf4df126e53/db970580eb704431af00101c67ba359c.jpg, createdBy=c6221962164, createdName=1e13ac83m50(暂无匿称), createdTime=Fri Dec 24 06:41:31 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069082, encodeId=4bfd106908210, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=289a5704354, createdName=ms1000001851068630, createdTime=Wed Nov 10 21:05:06 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062519, encodeId=f6231062519cd, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:53:45 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-11-10 ms1000001851068630

    谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1085784, encodeId=5e191085e8436, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cca5577874, createdName=ms2000002042000994, createdTime=Thu Dec 30 11:56:52 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084249, encodeId=289410842490d, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048e6414873, createdName=ms8000000343428426, createdTime=Sat Dec 25 21:38:15 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083752, encodeId=d7411083e5266, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211025/4aac53d3123446c5af3cebf4df126e53/db970580eb704431af00101c67ba359c.jpg, createdBy=c6221962164, createdName=1e13ac83m50(暂无匿称), createdTime=Fri Dec 24 06:41:31 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069082, encodeId=4bfd106908210, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=289a5704354, createdName=ms1000001851068630, createdTime=Wed Nov 10 21:05:06 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062519, encodeId=f6231062519cd, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12d75586812, createdName=ms8000001549818402, createdTime=Thu Oct 21 09:53:45 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-10-21 ms8000001549818402

    谢谢

    0

相关指南

《中国胰腺癌诊治指南（2021）》解读

暂未更新 · 2021-07-01

中国胰腺癌诊治指南（2021）

中华医学会外科学分会胰腺外科学组 · 2021-07-01

2021 AIOM_AMD_SIE_SIF多学科共识意见：新发糖尿病胰腺癌的早期预测

意大利肿瘤医学协会(AIOM,Italian Association of Medical Oncology) · 2021-05-18

中国胰腺癌综合诊治指南（2020版）

中国抗癌协会胰腺癌专业委员会 · 2020-01-18

2019 JPS临床实践指南：胰腺癌（概要）

日本胰脏学会(JPS,Japan Pancreas Society) · 2020-03-20

中华医学会肿瘤学分会胰腺癌早诊早治专家共识

中华医学会肿瘤学分会 · 2020-09-30